The HCA Midwest Health clinical research program supports overall patient care by offering another therapeutic option through clinical trials. These clinical studies are available through the Kansas City Clinical Oncology Program (KCCOP), Sarah Cannon Research Institute, and various pharmaceutical and CRO partners.

AML 40: A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia.
Facility: Research Medical Center

CLL 38: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia. PI: Suman Kambhampati, MD
Facility: Menorah Medical Center, Research Medical Center

CLL 39: A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304.. PI: Suman Kambhampati, MD
Facility: Menorah Medical Center, Research Medical Center

CLL 41: A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy.
Facility: Menorah Medical Center, Research Medical Center

LYM 119: A phase 2 study of Denintuzumab Mafodotin (SGN-CD19A) in combination with RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or RCHP (rituximab, cyclophosphamide, doxorubicin,and prednisone) compared with standard of care as frontline therapy in patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) Grade 3b. PI: Suman Kambhampati, MD
Facility: Menorah Medical Center, Research Medical Center

LYM 120: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma. PI: Suman Kambhampati, MD
Facility: Menorah Medical Center, Research Medical Center

LYM 122: A phase 3, randomized, double blind, placebo controlled, multicenter study of BR alone versus in combination with Acalabrutinib (ACP-196) in subjects with previously untreated mantle cell Lymphoma, radiologically measurable lymphadenopathy or extranodal lymphoid malignancy.
Facility: Menorah Medical Center, Research Medical Center

LYM 126: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma.
Facility: Menorah Medical Center, Research Medical Center

LYM 132: A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kδ Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MM 61: A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM).
Facility: Menorah Medical Center, Research Medical Center

MM 74: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients. PI: Suman Kambhampati, MD
Facility: Menorah Medical Center, Research Medical Center

BRE 231: A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study) PI: Stephanie Graff, MD
Facility: Menorah Medical Center, Research Medical Center

BRE 263: The impact of HER2 heterogeneity on the treatment of early-stage HER2-positive breast cancer: a phase II study of T-DM1 in combination with Pertuzumab in the preoperative setting. PI: Stephanie Graff, MD
Facility: Menorah Medical Center

BRE 273: A randomized controlled multicenter Phase IIa trial to evaluate the safety and immunogenicity of two doses of vaccination with Folate Receptor Alpha peptides with GM-CSF in patients with Triple Negative Breast Cancer PI: Stephanie Graff, MD
Facility: Menorah Medical Center, Research Medical Center

BRE 274: A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 290: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptorpositive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
Facility: Menorah Medical Center

  :  
Facility:  

GI 201 - INN: A Phase II Study of Nab-paclitaxel plus Ramucirumab for the Second-line Treatment of Patients with Metastatic Gastroesophageal Cancer. PI: Jaswinder Singh, MD
Facility: Research Medical Center

GI 221: A phase 2 study of lanreotide in patients with metastatic gastrointestinal neuroendocrine tumors undergoing liver-directed radioembolization with yttrium-90 microspheres (SIR-Spheres). PI: Jaswinder Singh, MD
Facility: Menorah Medical Center, Research Medical Center

GI 247: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer
Facility: Menorah Medical Center, Research Medical Center

GI 250: A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma
Facility: Menorah Medical Center, Research Medical Center

GU 118: An Open-Label, Non-randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY). PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 135: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemo-therapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma. PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 136: Phase IIIb/IV Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC. PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 137: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR).. PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 139: A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (antiƒ{pd-l1 antibody) in combination with Enzalutamide versus enzalutamide alone in patients with metastatic castration resistant prostate cancer after failure of an androgen synthesis inhibitor and failure of, ineligibility for, or refusal of a taxane regimen.
Facility: Menorah Medical Center, Research Medical Center

GU 142: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency. PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 147: A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind study of Atezolizumab (Anti-PD-L1 antibody) as adjuvant therapy in patients with PD-L1 selected renal cell carcinoma at intermediate to high risk of developing metastasis following nephrectomy.
Facility: Menorah Medical Center, Research Medical Center

GU 148: A phase III, randomized, double-blind, placebo-controlled, multicenter trial testing ipatasertib plus abiraterone plus prednisone/prednisolone, relative to placebo plus abiraterone plus prednisone/ prednisolone in patients with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer with pten-loss (pten diagnostic positive) tumors.
Facility: Menorah Medical Center, Research Medical Center

GYN 41: A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. PI: Kristopher LyBarger, MD
Facility: Research Medical Center

GYN 63: A Phase II Open-Label Study to Assess the Safety, Pharmacokinetics and Clinical Activity of Acelarin® (NUC-1031) Given on Days 1, 8 and 15 of a 28-Day Schedule in Patients with Recurrent Platinum-Resistant Ovarian Cancer.
Facility: Centerpoint Medical Center, Research Medical Center

GYN 66: A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation. PI: Kristopher LyBarger, MD
Facility: Research Medical Center

GYN 69: A Multicenter, Multinational, Double-blind, 2-Arm, Randomized, Phase 2/3, Study of Physician’s Choice Chemotherapy (PCC) (Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects with Platinum-Resistant, Recurrent, Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer. PI: Kristopher LyBarger, MD
Facility: Research Medical Center

GYN 70: A Randomized, Placebo-controlled, Double blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients with Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment with a Safety Lead-in.
Facility: Research Medical Center

GYN 72: A randomized multicenter Phase II trial to evaluate the safety, efficacy and immunogenicity of vaccination with Folate Receptor Alpha peptides admixed with GM-CSF as a vaccine adjuvant versus GM-CSF alone in patients with Platinum Sensitive Ovarian Cancer.
Facility: Research Medical Center

REFMAL 365: A Phase Ib Study evaluating the c-Met Inhibitor INC280 in Combination with Bevacizumab in Glioblastoma Multiforme (GBM), Patients. PI: Amandeep Kalra, MD
Facility: Menorah Medical Center, Research Medical Center

LUN 349: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU).
Facility: Menorah Medical Center, Research Medical Center

LUN 356: A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Small-Cell Lung Cancer (SCLC) Patients Receiving First-Line Standard of Care Platinum-Based Chemotherapy.
Facility: Menorah Medical Center, Research Medical Center

MEL 54: A phase III, double-blinded, randomized, placebo-controlled study of atezolizumab plus cobimetinib and vemurafenib versus placebo plus Cobimetinib and vemurafenib in previously untreated brafv600 mutation−positive patients withunresectable locally advanced or Metastatic melanoma.
Facility: Menorah Medical Center, Research Medical Center